Patrick G Lepore insider trades: VYNE Therapeutics (VYNE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Patrick reports to the SEC
Open-market buys and sales
29 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | VYNE | ↑ Buy | 15,000 | $2.92 | $44K | Direct | Jan 16, 2025 (1d) |
| Nov 15, 2023 | VYNE | ↑ Buy | 13,000 | $3.91 | $51K | Direct | Nov 17, 2023 (2d) |
| Mar 20, 2023 | VYNE | ↑ Buy | 20,000 | $2.48 | $50K | Direct | Mar 22, 2023 (2d) |
| Nov 10, 2022 | LCI | ↑ Buy | 100,000 | $0.49 | $49K | Direct | Nov 14, 2022 (4d) |
| May 16, 2022 | LCI | ↑ Buy | 50,000 | $0.54 | $27K | Direct | May 17, 2022 (1d) |
| Feb 8, 2022 | LCI | ↑ Buy | 50,000 | $0.88 | $44K | Direct | Feb 10, 2022 (2d) |
| Nov 30, 2021 | VYNE | ↑ Buy | 12,500 | $1.02 | $13K | Direct | Dec 2, 2021 (2d) |
| Nov 29, 2021 | LCI | ↑ Buy | 50,000 | $1.71 | $86K | Direct | Nov 30, 2021 (1d) |
| Sep 8, 2021 | LCI | ↑ Buy | 20,000 | $3.31 | $66K | Direct | Sep 9, 2021 (1d) |
| Aug 25, 2021 | VYNE | ↑ Buy | 12,500 | $1.60 | $20K | Direct | Aug 26, 2021 (1d) |
| May 26, 2021 | VYNE | ↑ Buy | 12,500 | $3.60 | $45K | Direct | May 27, 2021 (1d) |
| May 11, 2021 | LCI | ↑ Buy | 20,000 | $4.18 | $84K | Direct | May 12, 2021 (1d) |
| Mar 15, 2021 | VYNE | ↑ Buy | 12,500 | $7.41 | $93K | Direct | Mar 16, 2021 (1d) |
| Dec 3, 2020 | VYNE | ↑ Buy | 50,000 | $1.71 | $85K | Direct | Dec 7, 2020 (4d) |
| May 14, 2020 | MTNB | ↑ Buy | 100,000 | $0.73 | $73K | Direct | May 18, 2020 (4d) |
| Nov 15, 2019 | MTNB | ↑ Buy | 100,000 | $1.06 | $106K | Direct | Nov 19, 2019 (4d) |
| Sep 3, 2019 | LCI | ↑ Buy | 25,000 | $9.82 | $246K | Direct | Sep 5, 2019 (2d) |
| Aug 16, 2019 | MTNB | ↑ Buy | 100,000 | $0.72 | $72K | Direct | Aug 20, 2019 (4d) |
| May 16, 2019 | MTNB | ↑ Buy | 100,000 | $0.95 | $95K | Direct | May 20, 2019 (4d) |
| May 8, 2019 | LCI | ↑ Buy | 25,000 | $7.32 | $183K | Direct | May 9, 2019 (1d) |
| Feb 12, 2019 | LCI | ↑ Buy | 25,000 | $8.93 | $223K | Direct | Feb 13, 2019 (1d) |
| Dec 13, 2018 | LCI | ↑ Buy | 25,000 | $5.10 | $127K | Direct | Dec 17, 2018 (4d) |
| Aug 31, 2018 | LCI | ↑ Buy | 25,000 | $5.34 | $134K | Direct | Sep 4, 2018 (4d) |
| May 11, 2018 | LCI | ↑ Buy | 25,000 | $15.13 | $378K | Direct | May 14, 2018 (3d) |
| Sep 6, 2011 | PRX | ↑ Buy | 8,000 | $25.92 | $207K | By Trust | Sep 7, 2011 (1d) |
| May 9, 2011 | PRX | ↓ Sell | 65,467 | $34.17 | $2.2M | Direct | May 11, 2011 (2d) |
| Oct 17, 2008 | PRX | ↑ Buy | 5,000 | $10.58 | $53K | Direct | Oct 20, 2008 (3d) |
| Oct 3, 2007 | PRX | ↑ Buy | 15,000 | $18.36 | $275K | By Trust | Oct 4, 2007 (1d) |
| Oct 3, 2007 | PRX | ↑ Buy | 15,000 | $18.36 | $275K | By Limited Partnership | Oct 4, 2007 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Patrick G Lepore's insider trades
Patrick G Lepore is an insider at VYNE Therapeutics (VYNE). Since Oct 3, 2007, Patrick has reported 28 open-market purchases worth $3.2M and 1 sale worth $2.2M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (31 filings), shares withheld for taxes (19 filings), shares returned to the company (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VYNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.